Navigation Links
Celladon Provides MYDICAR(R) Program Update of First-In-Human Trial for Advanced Heart Failure at American Society of Gene Therapy Annual Meeting
Date:5/28/2009

Phase 1 Data Demonstrate Safety and Evidence of Biological Activity in 9 of 12 Patients;

Phase 2 Study Currently Enrolling in 17 Leading U.S. Medical Centers

SAN DIEGO, May 28 /PRNewswire/ -- Celladon Corporation presented today Phase 1 data from the Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID), a First-in-Human Phase 1/2 Clinical Trial, in a scientific symposium at the 12th Annual American Society of Gene Therapy Meeting.

The Phase 1 data showed that MYDICAR(R) had an acceptable safety profile in twelve patients, as determined by study investigators and an independent safety committee. In addition, improvements from baseline to six months were observed across a number of key efficacy parameters important in assessing heart failure status. Efficacy was defined as the mean improvement in at least 2 of 5 domains without any worsening in the remaining domains, including a functional six-minute walk test, oxygen consumption, quality of life questionnaire, biomarker activity and left ventricular size and function.

"We are encouraged by the meaningful improvements in cardiac function and overall condition of patients, findings that we believe demonstrate the return toward normal intracellular calcium cycling and contractility in some of the heart muscle cells of these very sick patients," said Krisztina M. Zsebo, Ph.D., president and chief executive officer. "Our extensive preclinical and clinical investigation to understand the molecular basis of myocardial dysfunction, together with the evolution of safe and efficient gene transfer technology, has placed gene-based therapy for heart failure within reach and yielded valuable insights for the entire field of study."

The Phase 1 open-label, sequential dose escalation, multi-center phase of the trial was designed to investigate safety and biological effects of restoring SERCA2a enzyme activity in heart muscle cells. The enzyme levels are decreased in late stages of heart failure, and extensive research shows loss of SERCA2a levels represents a common pathway resulting in a defect in the ability of the heart to contract properly. Replacing the enzyme may restore function and reverse heart failure.

The Phase 2 randomized, double-blind, placebo-controlled, parallel-group, dose ranging portion of the study is designed to evaluate the use of MYDICAR at two or three dose levels compared to placebo in 37 patients. CUPID is currently enrolling patients with advanced heart failure at 17 U.S. medical centers.

Zsebo adds, "We anticipate completion of Phase 2 enrollment late this summer and plan to report results in the first half of 2010. In addition, we have adequate MYDICAR product manufactured to complete Phase 3 and recently acquired exclusive license to utilize Adeno-Associated Viral (AAV) vector technology in heart failure, which bodes well for commercial product development of MYDICAR and important to potential strategic partners. "

Celladon scientists, led by company co-founder Roger J. Hajjar, M.D., Director of the Cardiovascular Research Center at Mount Sinai School of Medicine, New York, developed MYDICAR for restoring the SERCA2a calcium transporter in heart failure and validated the overall beneficial effects on cardiac function. MYDICAR is a recombinant adeno-associated viral (rAAV) vector that transfers the SERCA2a gene into heart muscle cells. MYDICAR is delivered in a single dose directly to the heart muscle during a short outpatient procedure, performed in a standard cardiac catheterization laboratory via a small incision in the upper leg.

Of the twelve patients treated, two with low levels of pre-existing antibodies to the AAV vector did not show improvement in these parameters. The data are consistent with safety established for other rAAV vectors, which has been demonstrated in clinical studies of more than 500 patients. AAV vectors are the product of decades of research focused on the safety of gene transfer agents, and are derived from components of a non-replicating, non-pathogenic, commonly occurring human virus. AAV vectors do not integrate into the chromosome and are considered non-mutagenic. In addition, they have not been associated with the types of inflammatory reactions observed in trials involving adenoviral vectors, which are known to induce acute inflammation of tissues due to activation of the body's immune system.

Patients with heart failure may assess eligibility to participate in the CUPID trial and download a patient questionnaire and additional information on MYDICAR to review with your physician by visiting www.celladon.net, under the "For Patients" tab.

About Heart Failure

Chronic heart failure is an increasingly important health problem. It is the leading medical cause of hospitalization and is expected to result in an estimated direct and indirect cost to the healthcare system in 2009 of $37.2 billion. About 5 million people in the United States have heart failure, and another 550,000 new cases are diagnosed each year. Heart failure contributes to or causes about 280,000 deaths annually. The most common symptoms of heart failure are shortness of breath, feeling tired, and swelling in the ankles, feet, legs, and sometimes the abdomen. There is no cure for heart failure.

About Celladon

Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The company's products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon's first product candidate, MYDICAR, delivers the gene for the SERCA2a enzyme. MYDICAR is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladon's website at www.celladon.net.


'/>"/>
SOURCE Celladon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy
2. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
5. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
6. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
7. USAID Provides $5M in Emergency Support as Swine Flu Spreads
8. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
11. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... titled, " Exocrine Pancreatic Insufficiency Market - Global Industry ... 2023 ." According to the report, the exocrine pancreatic ... of 8.3% from 2015 to 2023 to reach US$2.85 ... is a condition characterized by the deficiency of the ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... New Brunswick, New Jersey: This year marks Children’s Specialized Hospital ’s 125th ... the anniversary, the hospital has themed the milestone “Hats Off” and kicked off the ... on Saturday, May 21, at Johnson Park in Piscataway, New Jersey. , ...
(Date:5/24/2016)... — , ... (PRWEB) ... of three new members of its Advisory Board. Joining the ... Sarah Kusch. “All three of them embody the mission of our ... are very fortunate to have them as we continue to expand ...
(Date:5/24/2016)... ... ... Boyd Industries, a leading supplier of dental chairs and cabinetry , will ... dentistry , at AAPD 2016, the annual conference and trade show of the American ... keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery system out ...
(Date:5/24/2016)... Angeles, CA (PRWEB) , ... May 24, 2016 ... ... to everything egg freezing, today announced the official relaunch of its community and ... use their frozen eggs. Eggsurance's mission is to create a safe and welcoming ...
(Date:5/24/2016)... Maryland (PRWEB) , ... May 24, 2016 , ... ... announced the appointment of Jonathan (Jon) Otterstatter to its board of ... is a proven leader in the development of technological innovations that lead to ...
Breaking Medicine News(10 mins):